5 amino 1mq human clinical trial 5-amino-1mq Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice 5-amino-1mq clinical trial Reduced – Size:5mg 5-Amino-1MQ 5mg - True

5 amino 1mq human clinical trial 5-amino-1mq Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice 5-amino-1mq clinical trial Reduced – Size:5mg 5-Amino-1MQ 5mg - True

5-Amino-1MQ 5mg - True Form Peptides

A scientifically credible path to human use would require, at minimum, the following sequential steps: Step 1, IND-enabling preclinical package: A full GLP toxicology package including 28-day repeat-dose rat and dog studies, genotoxicity assays (Ames test, in-vitro micronucleus), cardiovascular safety pharmacology (hERG channel, in-vivo telemetry), and a non-human primate pharmacokinetic study to establish bioavailability, volume of distribution, and clearance

Size:5mg

The compound is a small-molecule methylquinolinium NNMT inhibitor sold alongside peptide products